Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2017

Open Access 01-12-2017 | Research article

Effect of microbial siderophores on mammalian non-malignant and malignant cell lines

Published in: BMC Complementary Medicine and Therapies | Issue 1/2017

Login to get access

Abstract

Background

Iron is a vital nutrient for all cells, and malignant cells have a higher requirement for the metal due to their rapid multiplication. Bacterial siderophores can be used to reduce free ferric ion concentration from the cellular environment.

Methods

In the present study, we have evaluated effect of three siderophores – exochelin-MS, mycobactin S and deferoxamine B on the proliferation of mammalian cell lines using MTT assay.

Results

These siderophores caused a significant decrease in the viability of malignant cells, without significantly affecting non-malignant cells.

Conclusions

Based on these results, we suggest that iron-chelation therapy could be explored as an adjunctive therapeutic option against cancer along with other therapies.
Literature
1.
Hoffbrand AV, Ganeshaguru K, Hooton JW, Tattersall MH. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol. 1976;33(4):517–26.CrossRefPubMed
2.
Richardson DR. Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol. 2002;42(3):267–81.CrossRefPubMed
3.
Cheng Z, Song Y, Xia J, Kang Y, Dai LL, Liu Y. Effect of iron on the proliferation of lung adenocarcinoma cells in vitro. African J Pharm Pharmacol. 2012;6(7):443–7.
4.
Ratledge C, Hall MJ. Influence of metal ions on the formation of mycobactin and salicylic acid in Mycobacterium smegmatis grown in static culture. J Bacteriol. 1971;108:314–9.PubMedPubMedCentral
5.
Sharman GJ, Williams DH, Ewing DF, Ratledge C. Isolation, purification and structure of exochelin MS, the extracellular siderophore from Mycobacterium smegmatis. Biochem J. 1995;305(1):187–96.CrossRefPubMedPubMedCentral
6.
7.
Barclay R, Ratledge C. Iron-binding compounds of Mycobacterium avium, M. intracellulare, M. scrofulaceum, and mycobactin-dependent M. paratuberculosis and M. avium. J Bacteriol. 1983;153:1138–46.PubMedPubMedCentral
8.
9.
Ratledge C, Snow GA. Isolation and Structure of Nocobactin NA, a Lipid-Soluble Iron-Binding Compound from Nocardia asteroids. Biochem J. 1974;139:407–13.CrossRefPubMedPubMedCentral
10.
11.
Freshney RI. Culture of Animal Cells Set. Med Clin (Barc). 2000;82:608.
12.
Ratledge C, Ewing M. The occurrence of carboxymycobactin, the siderophore of pathogenic mycobacteria, as a second extracellular siderophore in Mycobacterium smegmatis. Microbiol. 1996;142:2207–22.CrossRef
13.
Ratledge C, Ewing DF. The separation of the mycobactins from Mycobacterium smegmatis by using high-pressure liquid chromatography. Biochem J. 1978;175(3):853–7.CrossRefPubMedPubMedCentral
14.
Salis O, Bedir A, Kilinc V, Alacam H, Gulten S, Okuyucu A. The anticancer effects of desferrioxamine on human breast adenocarcinoma and hepatocellular carcinoma cells. Cancer Biomark. 2014;14(6):419–26.CrossRefPubMed
15.
Pahl PMB, Horwitz MA, Horwitz KB, Horwitz LD. Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells. Breast Cancer Res Treat. 2001;69(1):69–79.CrossRefPubMed
16.
Hoke EM, Maylock CA, Shacter E. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin. Free Radic Biol Med. 2005;39(3):403–11.CrossRefPubMed
17.
Blatt J, Stitely S. Antineuroblastoma Activity of Desferoxamine in Human Cell Lines. Cancer Res. 1987;47:1749–50.PubMed
18.
Dayani PN, Bishop MC, Black K, Zeltzer PM. Desferoxamine (DFO) – Mediated Iron Chelation: Rationale for a Novel Approach to Therapy for Brain Cancer. J Neuro-Oncol. 2004;67(3):367–77.CrossRef
19.
Hann H-WL, Stahlhut MW, Rubin R, Maddrey WC. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer. 1992;70(8):2051–6.CrossRefPubMed
20.
Estrov Z, Tawa A, Wang XH, Dube ID, Sulh H, Cohen A, Gelfand EW, Freedman H. In vitro and in vivo effects of Deferoxamine in Neonatal Acute Leukemia. Blood. 1987;69(3):757–61.PubMed
Metadata
Title
Effect of microbial siderophores on mammalian non-malignant and malignant cell lines
Publication date
01-12-2017
Published in
BMC Complementary Medicine and Therapies / Issue 1/2017
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-017-1657-8

Other articles of this Issue 1/2017

BMC Complementary Medicine and Therapies 1/2017 Go to the issue

Research article

The influence of Osmunda regalis root extract on head and neck cancer cell proliferation, invasion and gene expression

Research article

Dai-Huang-Fu-Zi-Tang alleviates pulmonary and intestinal injury with severe acute pancreatitis via regulating aquaporins in rats

Research article

Barriers to the conduct and application of research in complementary and alternative medicine: a systematic review

Research article

Appraisal of phytochemical and in vitro biological attributes of an unexplored folklore: Rhus Punjabensis Stewart

Research article

Practitioners’ perspectives on evaluating treatment outcomes in traditional Chinese medicine

Research article

Hypoglycemic effects of Trichosanthes kirilowii and its protein constituent in diabetic mice: the involvement of insulin receptor pathway